Viral safety of human platelet lysate for cell therapy and regenerative medicine: Moving forward, yes, but without forgetting the past

Published on Oct 31, 2019in Transfusion and Apheresis Science1.285
· DOI :10.1016/J.TRANSCI.2019.102674
Thierry Burnouf50
Estimated H-index: 50
Lassina Barro6
Estimated H-index: 6
(TMU: Taipei Medical University)
+ 4 AuthorsJerard Seghatchian27
Estimated H-index: 27
Abstract Growth factor-rich pooled human platelet lysate (HPL), made from human platelet concentrates, is one new blood-derived bioproduct that is attracting justified interest as a xeno-free supplement of growth media for human cell propagation for cell therapy. HPL can also find potentially relevant applications in the field of regenerative medicine. Therefore, the therapeutic applications of HPL go far beyond the standard clinical applications of the traditional blood products typically used in patients suffering from life-threatening congenital or acquired deficiencies in cellular components or proteins due to severe genetic diseases or trauma. A wider population of patients suffering from various pathologies than has traditionally been the case, is thus, now susceptible to receiving a human blood-derived product. These patients would, therefore, be exposed to the possible side effects of blood products, including transfusion-transmitted infections, most specifically virus transmissions. Unfortunately, not all manufacturers, suppliers, and users of HPL may have a strong background in the blood product industry. As such, they may not be fully aware of the various building blocks that should contribute to the viral safety of HPL as is already the case for any licensed blood products. The purpose of this manuscript is to reemphasize all the measures, including in regulatory aspects, capable of assuring that HPL exhibits a sufficient pathogen safety margin, especially when made from large pools of human platelet concentrates. It is vital to remember the past to avoid that the mistakes, which happened 30 to 40 years ago and led to the contamination of many blood recipients, be repeated due to negligence or ignorance of the facts.
📖 Papers frequently viewed together
6 Citations
20 Citations
1 Author (Albert Farrugia)
26 Citations
#2Reinhard HenschlerH-Index: 7
Last. Thierry Burnouf (TMU: Taipei Medical University)H-Index: 4
view all 5 authors...
Human platelet lysate (HPL), rich in growth factors, is an efficient alternative supplement to fetal bovine serum (FBS) for ex vivo propagation of stromal cell-based medicinal products. Since 2014, HPL has been a focus of the Working Party for Cellular Therapies of the International Society of Blood Transfusion (ISBT). Currently, as several Good Manufacturing Practice (GMP)-compliant manufacturing protocols exist, an international consensus defining the optimal modes of industrial production, pr...
20 CitationsSource
#1Majid Zamani (Tabriz University of Medical Sciences)H-Index: 24
#1Majid Zamani (Tabriz University of Medical Sciences)H-Index: 4
Last. Mehdi Yousefi (Tabriz University of Medical Sciences)H-Index: 36
view all 7 authors...
: Hemoderivative materials are used to treat different diseases. These derivatives include platelet-rich plasma, serum, platelet gel, and platelet lysate (PL). Among them, PL contains more growth factors than the others and its production is inexpensive and easy. PL is one of the proper sources of platelet release factors. It is used in cells growth and proliferation and is a good alternative to fetal bovine serum. In recent years, the clinical use of PL has gained more appeal by scientists. PL ...
14 CitationsSource
#1Karen Bieback (German Red Cross)H-Index: 41
#2Beatriz Fernandez-Muñoz (CSIC: Spanish National Research Council)H-Index: 2
Last. Richard Schäfer (German Red Cross)H-Index: 27
view all 4 authors...
Abstract Fetal bovine serum (FBS) is used as a growth supplement in a wide range of cell culture applications for cell-based research and therapy. However, as a xenogenic product, FBS can potentially transmit prions and adventitious viruses as well as induce undesirable immunologic reactions. In addition, the use of bovine fetuses for FBS production raises concerns as society looks for ways to replace animal testing and reduce the use of animal products for scientific purposes, in particular for...
12 CitationsSource
#1Lassina Barro (TMU: Taipei Medical University)H-Index: 6
#2Yu Ting Su (TMU: Taipei Medical University)H-Index: 2
Last. Thierry Burnouf (TMU: Taipei Medical University)H-Index: 50
view all 8 authors...
BACKGROUND: Pooled human platelet lysate (HPL) can replace fetal bovine serum (FBS) as xeno-free supplement for ex vivo expansion of mesenchymal stromal cells (MSCs). We evaluate here whether a double-virally-inactivated HPL (DVI-HPL) prepared from expired Intercept-treated platelet concentrates (PCs) and treated by solvent/detergent (S/D) can be used for MSC expansion. STUDY DESIGN AND METHODS: Expired Intercept-treated PCs in 65% platelet (PLT) additive solution were pooled and subjected to a ...
12 CitationsSource
#1Reinhard HenschlerH-Index: 7
#2Christian Gabriel (University of Vienna)H-Index: 8
Last. Mickey Koh (St George's Hospital)H-Index: 25
view all 5 authors...
: A state-of-the-art workshop focused on the use of human platelet lysate (HPL) for cell therapy. The meeting established that HPL is used mainly as an adjunct material for ex vivo expansion of mesenchymal stem/progenitor cells (MSCs), where it is successfully used as a substitute for fetal bovine serum. HPL manufacturing as a cell expansion supplement is currently not yet uniformly standardized with regard to platelet source and production methodology. There are very few reports of HPL preparat...
22 CitationsSource
#1Sabrina ViauH-Index: 5
#2Sandy EapH-Index: 4
Last. Bruno DelormeH-Index: 25
view all 5 authors...
BACKGROUND: Human platelet lysate (hPL) represents a powerful medium supplement for human mesenchymal stromal cell (hMSC) expansion. The recently published general chapters of the Pharmacopeia require the addition of a step of viral inactivation during the production process of such raw biological material used for cell-based medicinal products. STUDY DESIGN AND METHODS: The ability of gamma irradiation to inactivate viruses from a panel representative of the virus diversity was evaluated. The i...
11 CitationsSource
#1John R. Ticehurst (Johns Hopkins University)H-Index: 30
#2Nora Pisanic (Johns Hopkins University)H-Index: 14
Last. Kenrad E. Nelson (Johns Hopkins University)H-Index: 92
view all 11 authors...
BACKGROUND: Hepatitis E virus (HEV) can inapparently infect blood donors. To assess transfusion transmission of HEV in the United States, which has not been documented, a donor-recipient repository was evaluated. STUDY DESIGN AND METHODS: To identify donations that contained HEV RNA and were linked to patient-recipients with antibody evidence of HEV exposure, we assayed samples from the Retrovirus Epidemiology Donor Study (REDS) Allogeneic Donor and Recipient repository that represents 13,201 li...
8 CitationsSource
#1Elaheh Jooybar (Sharif University of Technology)H-Index: 5
#2Mohammad J. Abdekhodaie (RyeU: Ryerson University)H-Index: 20
Last. Pieter J. Dijkstra (UT: University of Twente)H-Index: 62
view all 6 authors...
Abstract Developing scaffolds that can provide cells and biological cues simultaneously in the defect site is of interest in tissue engineering field. In this study, platelet lysate (PL) as an autologous and inexpensive source of growth factors was incorporated into a cell-laden injectable hyaluronic acid-tyramine (HA-TA) hydrogel. Subsequently, the effect of platelet lysate on cell attachment, viability and differentiation of human mesenchymal stem cell (hMSCs) toward chondrocytes was investiga...
35 CitationsSource
#1Ute Gravemann (German Red Cross)H-Index: 13
#2Wiebke Handke (German Red Cross)H-Index: 6
Last. Axel Seltsam (German Red Cross)H-Index: 25
view all 6 authors...
BACKGROUND: Nonenveloped transfusion-transmissible viruses such as hepatitis A virus (HAV) and hepatitis E virus (HEV) are resistant to many of the common virus inactivation procedures for blood products. This study investigated the pathogen inactivation (PI) efficacy of the THERAFLEX UV-Platelets system against two nonenveloped viruses: HAV and feline calicivirus (FCV), in platelet concentrates (PCs). STUDY DESIGN AND METHODS: PCs in additive solution were spiked with high titers of cell cultur...
6 CitationsSource
#1Raymond P. Goodrich (CSU: Colorado State University)H-Index: 41
#2Jerard SegatchianH-Index: 3
Abstract Pediatric patients requiring transfusion constitute one of the most challenging areas of transfusion practice. Due to the limitations posed by their particular physiological conditions they routinely require specialized component support and more personalised transfusion care than what is routinely utilized in the care of adult patients. Pediatric patients, unlike many adult patients requiring transfusion support, also generally have significant lifespans post-transfusion. This combined...
10 CitationsSource
Cited By9
#1Meghan Alice Robinson (UBC: University of British Columbia)H-Index: 1
#2Ryan Flannigan (UBC: University of British Columbia)H-Index: 10
Last. Stephanie M. Willerth (UVic: University of Victoria)H-Index: 24
view all 0 authors...
In vitro expansion of spermatogonial stem cells (SSCs) has been established using animal-derived fetal bovine serum (FBS) and bovine serum albumin (BSA). However, the use of animal components during cell culture introduces the risk of contaminating cells with pathogens, and leads to animal epitope expression, rendering them unsuitable for medical use. Therefore, this study set out to develop a xeno-free, fully defined media for the expansion of human SSCs. We show that the molecules Prostaglandi...
Numerous cell-based therapeutics are currently being tested in clinical trials. Human platelet lysate (HPL) is a valuable alternative to fetal bovine serum as a cell culture medium supplement for a variety of different cell types. HPL as a raw material permits animal serum-free cell propagation with highly efficient stimulation of cell proliferation, enabling humanized manufacturing of cell therapeutics within a reasonable timeframe. Providers of HPL have to consider dedicated quality issues reg...
#1Andrea Pennati (UW: University of Wisconsin-Madison)H-Index: 12
#2Taylor M Apfelbeck (UW: University of Wisconsin-Madison)
Last. Jacques Galipeau (UW: University of Wisconsin-Madison)H-Index: 66
view all 4 authors...
Mammalian platelets participate in the immediate tissue injury response by initiating coagulation and further promoting tissue injury mitigation and repair. The latter properties are deployed follo...
#1Isabel Andia (QMUL: Queen Mary University of London)H-Index: 39
#1Isabel Andia (UNISA: University of Salerno)H-Index: 1
Last. Nicola MaffulliH-Index: 130
view all 2 authors...
Sports injuries and secondary joint problems, mainly of the knee, are common, especially in sports associated with high impact activities and/or torsional loading. The consequences can be career en...
#1Lassina Barro (TMU: Taipei Medical University)H-Index: 6
Last. Thierry Burnouf (TMU: Taipei Medical University)H-Index: 50
view all 9 authors...
A pathogen-free and standardized xeno-free supplement of growth media is required for the ex vivo propagation of human cells used as advanced therapeutic medicinal products and for clinical translation in regenerative medicine and cell therapies. Human platelet lysate (HPL) made from therapeutic-grade platelet concentrate (PC) is increasingly regarded as being an efficient xeno-free alternative growth medium supplement to fetal bovine serum (FBS) for clinical-grade isolation and/or propagation o...
1 CitationsSource
#1Nai-Chen Cheng (NTU: National Taiwan University)H-Index: 20
#2Yuan-Kun Tu (ISU: I-Shou University)H-Index: 4
Last. Tai-Horng Young (NTU: National Taiwan University)H-Index: 59
view all 4 authors...
Adipose-derived stem cell (ASC) is a valuable source of cell therapy. By stimulating extracellular matrix (ECM) secretion, ASC sheets can be fabricated with enhanced regenerative capabilities. In recent years, human platelet lysate (HPL) provides an attractive alternative to fetal bovine serum (FBS) for the ex vivo expansion of ASCs for clinical use. However, the effect of HPL on ASC sheet formation has not been previously determined. In this study, we compared ECM composition and cellular chara...
1 CitationsSource
#1Silvia Palombella (UNIL: University of Lausanne)H-Index: 1
#2Martino Guiotto (Glas.: University of Glasgow)H-Index: 1
Last. Pietro G. di SummaH-Index: 13
view all 9 authors...
The autologous nerve graft, despite its donor site morbidity and unpredictable functional recovery, continues to be the gold standard in peripheral nerve repair. Rodent research studies have shown promising results with cell transplantation of human adipose-derived stem cells (hADSC) in a bioengineered conduit, as an alternative strategy for nerve regeneration. To achieve meaningful clinical translation, cell therapy must comply with biosafety. Cell extraction and expansion methods that use anim...
1 CitationsSource
#1Lassina Barro (TMU: Taipei Medical University)H-Index: 6
#2Ouada Nebie (TMU: Taipei Medical University)H-Index: 4
Last. Thierry Burnouf (TMU: Taipei Medical University)H-Index: 50
view all 9 authors...
Abstract Background and aims: Human platelet lysate can replace fetal bovine serum (FBS) for xeno-free ex vivo expansion of mesenchymal stromal cells (MSCs), but pooling of platelet concentrates (PCs) increases risks of pathogen transmission. Herein, we evaluated the feasibility of performing nanofiltration of platelet lysates and determined the impact on expansion of bone marrow-derived MSCs. Methods: Platelet lysates were prepared by freeze-thawing of pathogen-reduced (Intercept®) PCs suspende...
4 CitationsSource
#1Milos Bohonek (CTU: Czech Technical University in Prague)H-Index: 4
#2Dominik Kutac (University of Defence)H-Index: 2
Last. Jerard SeghatchianH-Index: 27
view all 4 authors...
ABSTRACT The essential historical knowledge and expertise developed over the past 5-6 decades on the safety / efficacy of conventional blood components therapy by blood transfusion establishments have guided the development of validated methods which have ensure optimal safety margins for frozen blood and its bioproducts with or even without pathogen inactivation. Newer generations of pathogen reduced frozen red blood cell, plasma and platelet products and the standardised and safer pooling of h...
6 CitationsSource
#1Andrea Acebes-Huerta (International Sleep Products Association)H-Index: 10
#1Andrea Acebes-Huerta (International Sleep Products Association)H-Index: 2
Last. Laura Gutierrez (University of Oviedo)H-Index: 25
view all 7 authors...
Abstract Platelet derived bio-products in the form of platelet rich plasma, plasma rich in growth factors, or plasma-free platelet releasates, are being studied worldwide with the aim of proving their efficacy in tissue regeneration within many different clinical areas, such as traumatology, maxillofacial surgery, ophthalmology, dermatology and otorhinolaryngology, amongst others. The current lack of consensus in the preparation method and application form, or in the quality assessment of each b...
7 CitationsSource